SLC5A2 and heart failure: Body weight and fasting plasma glucose and insulin were lower in the dapagliflozin-treated groups compared with vehicle controls; dapagliflozin treatment also markedly increased fasting plasma NEFAs and circulating βOHB levels in sham-surgery and heart-failure rats, indicative of SGLT2 inhibition (Figure 6, A–E).